Peer Review reports
From: Optimal therapy for concomitant EGFR and TP53 mutated non-small cell lung cancer: a real-world study
| Original Submission | ||
|---|---|---|
| 7 Nov 2022 | Submitted | Original manuscript |
| Resubmission - Version 2 | ||
| Submitted | Manuscript version 2 | |
| Resubmission - Version 3 | ||
| Submitted | Manuscript version 3 | |
| 18 Dec 2022 | Reviewed | Reviewer Report - In Ae Kim |
| 1 Jan 2023 | Reviewed | Reviewer Report |
| 15 Jan 2023 | Author responded | Author comments - Zhansheng Jiang |
| Resubmission - Version 4 | ||
| 15 Jan 2023 | Submitted | Manuscript version 4 |
| 24 Jan 2023 | Author responded | Author comments - Zhansheng Jiang |
| Resubmission - Version 5 | ||
| 24 Jan 2023 | Submitted | Manuscript version 5 |
| Publishing | ||
| 13 Feb 2023 | Editorially accepted | |
| 2 Mar 2023 | Article published | 10.1186/s12885-023-10637-4 |
You can find further information about peer review here.